Assets
AstraZeneca plc - is Englishthe Swedish a pharmaceutical company registered in. Great Britain It is one of the largest global. pharmaceutical manufacturers
Performance indicators
2024: AstraZeneca becomes first company in Britain worth £200bn
In August 2024, AstraZeneca became the first company registered in Britain to reach a valuation of £200bn.
2023: On the list of companies with the largest R&D costs
For Amazon shows the costs of technology and content (not R&D).
ByteDance statistics date back to 2021 (according to the Wall Street Journal)
2022: Revenue growth 25% to $44.35 billion
At the end of 2022, the pharmaceutical company AstraZeneca received revenue of $44.35 billion. This is 25% more compared to the result of about $37.41 billion shown a year earlier. Such data are given in the financial report published on February 9, 2023.
AstraZeneca's net profit in 2022 was $3.29 billion. For comparison: a year earlier, this figure was $115 million. Thus, almost 30-fold growth has been demonstrated. It is noted that by the end of 2022, a decrease in revenues from the COVID-19 vaccine began to have a negative impact on the company's revenue.
AstraZeneca received a record 34 new drug approvals in major markets in 2022. The company is embarking on new clinical trials in late-stage high-potential drugs such as kamisestrant, datopotomab, deruxtecan and volrustomig. Until 2030, AstraZeneca expects to bring at least 15 new drugs to the market.
In 2022, approximately $43 billion of the total revenue was brought by sales of products. The growth in this area compared to the previous year amounted to 24%. Another $1.35 billion came from cooperation revenues and joint projects. The growth compared to 2021 is 56%. In 2023, the company expects double-digit revenue growth excluding drugs from COVID-19.
 | The company will continue to invest in drugs in development as well as recent launches while continuing to improve margins. In 2023, we plan to initiate more than thirty phase III trials, ten of which in peak years could potentially provide sales in excess of one billion dollars, said Pascal Soriot, Chief Executive Officer of AstraZeneca. |  |
2021: Revenue growth 41% to $37.42 billion
On February 10, 2022, the international scientific-oriented biopharmaceutical company AstraZeneca shared the results for 2021 with Zdrav.Expert. Due to the successful launch of new drugs on the market, a versatile development portfolio, as well as strategic transformation in connection with the acquisition of Alexion, AstraZeneca showed strong performance in the reporting year.
Photo: khn.org
Thus, at the end of 2021, the company's total revenue increased by 41% (by 38% at a constant exchange rate) to $37.42 billion, including revenues from the COVID-19 vaccine. Total revenue excluding the vaccine increased by 26% (23% at a constant exchange rate) to $33.436 billion.
Underlying earnings per share increased 32% for the year to $5.29 (vs. $4.02 in fiscal 2020). Reported earnings per share were $0.08 (vs. $2.44 in fiscal 2020).
In 2021, 14 phase III trials were successfully conducted for 9 medicinal products. There were also 22 regulatory approvals and approvals in major markets.
| | "In 2021, AstraZeneca continued to follow a high growth rate. We have achieved record sales of five of our drugs, acquired and integrated Alexion. We have fulfilled our promises to expand access to our COVID-19 vaccine by delivering 2.5 billion doses worldwide, "said Pascal Sorio, Chief Executive Officer of AstraZeneca. | |
According to him, all strategic directions of the company developed evenly. AstraZeneca achieved double-digit growth in all major markets, including countries those with emerging markets. economy
| | 2021 has become a landmark year for AstraZenek, so we intend to increase dividends for our stakeholders, "added Pascal Sorio. | |
Business in Russia
Main article: AstraZeneca Russia
History
2024
AstraZeneca China president Leon Wang under investigation in China
AstraZeneca China president Leon Wang is under investigation by Chinese authorities in October 2024, the drugmaker announced, adding that it was "cooperating with the investigation."
Wang played a crucial role in AstraZeneca's success in China, where it generated $5.9 billion in revenues in 2023, making it the largest overseas drugmaker by sales.
Investing 8 billion tenge in research and production of drugs in Kazakhstan
AstraZeneca invests 8 billion tenge in drug research and production in Kazakhstan. The company told about this in September 2024.
AstraZeneca has signed a contract production agreement with Nobel Almaty Pharmaceutical Factory and plans to launch the production of an innovative drug for the treatment of chronic kidney disease, heart failure and type 2 diabetes - dapagliflozin. The first batch of the original drug will enter the Kazakhstan market in 2025.
Acquisition of Amolyt Pharma
On July 15, 2024, AstraZeneca announced the successful completion of the acquisition of medical biotechnology company Amolyt Pharma, specializing in the development of drugs for the treatment of rare endocrine diseases. Read more here.
2023
Plan to buy China's Gracell Biotechnologies for up to $1.2 billion
AstraZeneca is set to make one of its first acquisitions in China, announcing plans in December 2023 to buy Gracell Biotechnologies for up to $1.2 billion to boost its investment in cell therapy for cancer treatment.
Creation of Evinova
On November 20, 2023, the British-Swedish pharmaceutical corporation AstraZeneca announced the formation of its first medical technology company. The new organization, called Evinova, will develop solutions based on artificial intelligence. Read more here.
$1.8 billion CinCor Pharma purchase
On January 9, 2023, AstraZeneca announced the acquisition of American drug developer CinCor Pharma for $1.8 billion. Thanks to this deal, the buyer expects to expand his range of medicines for the heart and kidneys. Read more here.
2022
Purchase of Neogene for $320 million
At the end of November 2022, AstraZeneca announced the purchase of Neogene Therapeutics for $320 million. Under the terms of the agreement, the company sold will first receive $200 million, and the remaining $120 million will be distributed within several tranches. Read more here.
AstraZeneca Patient Data Breach
On November 3, 2022, the pharmaceutical giant AstraZeneca called the "user error" the reason why a list of credentials left on the Internet for more than a year opened access to confidential patient data.
Mossab Hussain, chief security officer at startup SpiderSilk, said in an interview that in 2021, one of the developers left credentials for AstraZeneca's internal server on GitHub. Credentials gave access to Salesforce's test cloud environment, which is often used by companies to manage their customers, but the test environment contained some patient data, Hussain said.
Some of the data referred to AZ&ME apps that offer discounts to patients in need of medication. After the interview was published, the GitHub repository containing credentials became unavailable a few hours later.
| | In a statement, AstraZeneca spokesman Patrick Barth said: Protecting personal data is extremely important to us and we are committed to the highest standards and compliance with all applicable rules and laws. Due to a user error, some data records were temporarily available on the developer platform. We stopped accessing this data immediately after we were informed. We are investigating the root cause as well as assessing our regulatory obligations. | |
Bart declined to say why the patients' data was stored in the test environment, and whether AstraZeneca had technical tools, such as logs, to determine whether anyone had access to the data and what data, if any, had been deleted.
Credentials such as usernames and passwords revealed or accidentally published on sites such as GitHub have become an increasingly common find for security researchers. Over the past few years, open data has been uncovered from Samsung, controversial facial recognition startup Clearview AI and relaunched movie subscription service MoviePass. In August 2022, it was discovered that the credentials of Microsoft employees were also published on the GitHub website.[2]
AstraZeneca through the court forbade the ex-leader to move to GSK
On September 1, 2022, it became known that AstraZeneca managed to stop the former top manager from moving to work for rival GSK after the High Court in London granted an injunction during a trial between the two largest pharmaceutical companies in the UK. Read more here.
Payment of $775 million for theft of developments when creating a drug for the treatment of sclerosis
On March 17, 2022, the Anglo-Swedish drugmaker AstraZeneca announced that it would pay $775 million to resolve a patent dispute with Japan's Chugai Pharmaceutical. The legal dispute was related to the popular medical drug for the treatment of rare diseases Ultomiris.
AstraZeneca and Chugai Pharmaceutical will withdraw their patent infringement claims filed in the United States and Japan in early 2018 as one part of the settlement, the companies said in a statement. AstraZeneca will reflect the settlement payment as expenses in the results of the first quarter of 2022, and the payment itself will not affect its annual financial forecasts.
The medical drug Ultomiris, whose sales in 2021 amounted to about $700 million, was developed by AstraZeneca's rare disease division Alexion. The US drug division was acquired by AstraZeneca in 2021 for $39 billion.
The drug was originally developed as a treatment for neurological disease, like amyotrophic lateral sclerosis, but Alexion's division stopped these works in 2021 after a lack of efficacy in late-stage trials. For March 2022, Ultomiris is approved in some markets, as a treatment for two rare diseases of atypical hemolytic-uremic syndrome affecting kidney function, as well as a serious blood disease called paroxysmal nocturnal hemoglobinuria.[3]
2021
Purchase of rare disease drug manufacturer Caelum Biosciences
At the end of September 2021, Alexion AstraZeneca exercised its option in a transaction worth up to $500 million to acquire all remaining shares of Caelum Biosciences. The deal aims to get the buyer a CAEL-101 product, potentially first-in-class fibrillar-reactive monoclonal antibodies (mAbs) for the treatment of light chain amyloidosis. More. here
The AstraZeneca vaccine produced in Russia was called "R-Covi"
On March 12, 2021, the name became known, coronavirus vaccines COVID-19 which, under the license of the British pharmaceutical company AstraZeneca Oxford University , will be produced by the Russian company "." R-Pharm More. here
Sale of a stake in the biotech company Moderna in the amount of $1.2 billion
In early March 2021, it became known that the British pharmaceutical company AstraZeneca sold its stake in the biotechnology company Moderna for an amount estimated at $1.2 billion. Read more here.
2020
Revenue growth by 10% to $26.6 billion
On February 11, 2021, the international science-oriented bio pharmaceutical company AstraZeneca shared with Zdrav.Expert financial the results for 2020.
.jpg)
Photo source: mosmedpreparaty.ru
In general, in 2020, AstraZeneca demonstrated results in accordance with the forecast. The company's revenue in 2020 increased by 10% compared to the previous year and reached $26.6 billion, where sales amounted to $25.9 billion (25 890 000 000 US dollars). Revenue from sales of new drugs increased by 33%. These are drugs for the treatment of cancer and biopharmaceuticals, including Tagrisso ($4.3 billion) and Forsiga ($1.9 billion). The growth in sales of these medicines for the year amounted to 36% and 27%, respectively.
| | More than half of the annual revenue came from new drugs, which also led to an increase in profitability, while the growth strategy through innovation made it possible to provide additional benefits for patients, AstraZenek noted. - AstraZenek's patient-oriented strategy, focus on innovation and resource allocation priorities remain unchanged, with sustained long-term growth in revenue, profit and cash receipts continuing. | |
The company also said that in the fourth quarter of 2020, sales exceeded $7 billion for the first time in many years. USA
Sales of drugs in Russia in 2020 increased by 28% and amounted to $314 million.
| | In 2020, AstraZeneca took a big step forward. Despite the pandemic, we managed to achieve double-digit revenue growth, increase profitability and cash receipts. The continuous improvement of our portfolio of drugs, the high pace of development of our business and the progress in the development of a vaccine against COVID-19 have demonstrated what we can achieve, and the proposed acquisition of Alexion is designed to further accelerate our scientific and commercial evolution. The additional investments ensured the further growth of our oncology and biopharmaceutical areas. I am confident that in the future we will continue to achieve equally strong and compelling results and even greater progress for patients due to the focus on a good portfolio of drugs and consistency in our work, said Pascal Sorio, Chief Executive Officer of AstraZeneca
| |
Global Cancer Drug Market Share - 6.9%
AstraZeneca's share of the global cancer drug market was 6.9% (Evaluate data). Read more here.
Buying rare disease drug developer Alexion Pharmaceuticals
In mid-December 2020, AstraZeneca acquired rare disease drugmaker Alexion Pharmaceuticals for $39 billion in cash and stock. It is AstraZeneca's largest deal since it was founded in 1999. Read more here.
AstraZeneca sold the rights to Atakand to Cheplapharm Arzneimittel
At the end of October 2020, AstraZeneca sold the commercial rights to two of its drugs to the German pharmaceutical company Cheplapharm Arzneimittel. The business for the production of cardiovascular drugs Atakand and Atakand Plus was given for $400 million. Read more here.
Development of a vaccine against COVID-19
Main article: AstraZeneca vaccine against COVID-19
Plan to invest $1bn in Target: Zero Carbon Emissions program
On February 17, 2020, the international biopharmaceutical company AstraZeneca announced the interim results of the Ambition Zero Carbon program, during which it pledges to reduce carbon emissions from production activities around the world by 2025, and by 2030 to ensure negative carbon emissions from the company's operations through the implementation of ten-year decarbonization plans.
The "Goal: Zero Carbon Emissions" program is designed in accordance with scientific achievements in the field of ecology and provides measures to allow AstraZenek to double energy efficiency by using renewable energy for heating and lighting offices. In addition, there are plans to completely transfer the company's fleet to electric vehicles, which will happen five years ahead of schedule.
Within the framework of the Target: Zero Carbon Emissions program, AstraZeneca takes responsibility for achieving carbon neutrality without using carbon compensation schemes. To achieve these goals, the company will invest up to US $1 billion. This amount will also include the cost of developing the latest generation of respiratory inhalers with minimal potential to influence global warming. The company aims to ensure that the propellant used in the inhaler has 90-99% less environmental impact than the propellant used in previous models.
The plan also includes the AstraZenek Forest Forest Restoration Initiative, which will plant 50 million trees over the next 5 years. The first trees will be planted in Australia in February 2020 in partnership with local authorities and non-profit One Tree Planted, which works to restore forests around the world. Planted trees will also be planted in France, Indonesia and other countries of AstraZenek's presence. This program supports the recently launched World Economic Forum (WEF) global One Trillion Trees Initiative.
Another step towards the early decarbonization of the global economy is the entry of AstraZenek Chief Executive Officer Pascal Sorio into the Sustainable Markets Council (SMC). The Council was established by HRH the Prince of Wales with the support of the World Economic Forum as an advisory body for public and private individuals involved in charity work. The goal is to develop sustainable solutions in accordance with the United Nations sustainable development goals.
| | Climate change is a major threat to public health, the environment and the sustainability of the global economy. Since 2015, we have reduced greenhouse gas emissions from production activities by almost a third, and water consumption by almost a fifth. But the time has come to act even faster and redouble our efforts. The commitments made by AstraZeneca under the "Ambition Zero Carbon" strategy will accelerate the reduction of the company's climate impact and encourage global cooperation to change international policies. stated Pascal Sorio, Chief Executive Officer of AstraZeneca
| |
2019
Drug sales revenue growth 12% to $23bn $565m
On February 19, 2020, AstraZeneca reported to Zdrav.Expert about strong performance in 2019 - revenue from sales of drugs increased by 12% (15% at constant exchange rates) to the level of 23 billion 565 million US dollars. Sales of drugs increased by + 59% (+ 62% at constant exchange rates), emerging markets showed growth of + 18% (+ 24% at constant exchange rates).
For the first time in the history of the company, about half of the total revenue per year was sales of drugs for specialized medical care (cancer drugs, Brilinta, Lokelma and Fasenra). Sales of the company's drugs in Russia in 2019 increased by 35% (40% at constant exchange rates).
2019 for AstraZenek was marked by a significant increase in revenue, along with a long term and obtaining approvals of emerging drugs, as well as further significant progress in the pipeline development. This trend will continue in 2020, which will be accompanied by an increase in company revenues and an increase in net cash flow. Keeping committed to science and putting the interests of patients at the center of its activities, AstraZeneca will continue to realize its strategic ambitions.
| | In the first full year of our return to growth, we made significant progress in line with our strategy. The sales results of emerging drugs and advances in emerging markets were accompanied by positive news for patients on approval of drugs such as Enhertu for breast cancer therapy and Calquence for leukemia. Our partner projects have also evolved, including one with Daiichi Sankyo. In addition, at the end of 2019, several of our drugs received approval in China, including Linparza in the first-line therapy for ovarian cancer. We expect 2020, driven by a strong team, to be another year of success for AstraZenek. We are becoming a more balanced business thanks to our drugs in every region of presence. This transformation is another step to improve operational efficiency and increase net cash flow. While meeting our commitments to achieve long-term climate change and decarbonization goals, we will continue to focus on implementing our science and patient focused strategy, said Pascal Sorio, Chief Executive Officer of AstraZeneca
| |
Main therapeutic areas of AstraZeneca
As of April 2019, AstraZeneca is an international innovative biopharmaceutical company aimed at the research, development and commercial use of prescription drugs in several therapeutic areas - oncology, cardiology, nephrology, metabolism and respiratory diseases. The company is also selectively active in areas such as autoimmune diseases, neurology and infectious diseases. AstraZeneca is represented in more than 100 countries, and its innovative drugs are used by millions of patients around the world.
2017:31 plants in 20 countries
As of April 2017, AstraZeneca owns 31 plants in 20 countries and 11 research centers in 7 countries.
1999: AstraZeneca Education
The company was formed in 1999 as a result of the merger of the Swedish company Astra AB and the English Zeneca Group plc.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |